Další formáty:
BibTeX
LaTeX
RIS
@article{2306558, author = {Kubeš, Václav and Křen, Leoš and Sokol, Filip and Michalka, Jozef and Mužík, Jan and Arpáš, Tomáš and Křenová, Zdenka and Král, Zdeněk}, article_location = {ATHENS}, article_number = {4}, doi = {http://dx.doi.org/10.21873/invivo.13261}, keywords = {Classic Hodgkin lymphoma; PD-L1 expression; treatment; overall survival; relapse}, language = {eng}, issn = {0258-851X}, journal = {In vivo}, title = {Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases}, url = {https://iv.iiarjournals.org/content/37/4/1735}, volume = {37}, year = {2023} }
TY - JOUR ID - 2306558 AU - Kubeš, Václav - Křen, Leoš - Sokol, Filip - Michalka, Jozef - Mužík, Jan - Arpáš, Tomáš - Křenová, Zdenka - Král, Zdeněk PY - 2023 TI - Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases JF - In vivo VL - 37 IS - 4 SP - 1735-1742 EP - 1735-1742 PB - Greece : International Institute of Anticancer Research SN - 0258851X KW - Classic Hodgkin lymphoma KW - PD-L1 expression KW - treatment KW - overall survival KW - relapse UR - https://iv.iiarjournals.org/content/37/4/1735 N2 - Background/Aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis. Patients and Methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL). Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow -up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL. Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL. ER -
KUBEŠ, Václav, Leoš KŘEN, Filip SOKOL, Jozef MICHALKA, Jan MUŽÍK, Tomáš ARPÁŠ, Zdenka KŘENOVÁ a Zdeněk KRÁL. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2023, roč.~37, č.~4, s.~1735-1742. ISSN~0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.13261.
|